Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
OBJECTIVE
We evaluated the characterization and detection of liver lesions using mangafodipir trisodium.


METHODS
A total of 51 patients with liver lesions [13 hepatocellular carcinomas, 18 metastases, 14 hemangiomas, three cholangiocellular carcinomas, two hydatic cysts, and one focal nodular hyperplasia (FNH)] were examined by unenhanced and mangafodipir trisodium-enhanced MRI.


RESULTS
After administration of mangafodipir trisodium by slow intravenous infusion, mangafodipir trisodium-enhanced MRI was performed at 15-30 min and 24 h. The enhancement appeared in normal liver parenchyma and all of the hepatocellular lesions (HCCs and FNH). The lesions in hepatocellular carcinomas patients showed a non-homogeneous enhancement pattern. Non-hepatocellular lesions (hemangiomas, metastases, CCCs) had no enhancement on mangafodipir trisodium-enhanced MRI examinations. The rim-like enhancement pattern was demonstrated in all patients with cholangiocellular carcinomas, and in 14 metastases and 11 hemangiomas.


CONCLUSIONS
Mangafodipir trisodium-enhanced MRI permits reliable distinction between hepatocellular and non-hepatocellular tumors. Mangafodipir trisodium-enhanced MRI can show more functional and morphologic features of hepatocellular lesions. Some non-hepatocellular lesions which went undetected on unenhanced MRI were visualized after contrast enhancement of the liver. The rim-like enhancement pattern is not specific for metastases. Mangafodipir trisodium-enhanced MRI is safe and well tolerated and may aid in noninvasive diagnosis of liver lesions.
Karabacakoğlu
Aydin
A
Department of Radiology, Selçuk University, Meram Medical Faculty, Konya, Turkey. radaydin@hotmail.com
Adigüzel
Yüksel
Y
Karaköse
Serdar
S
Kayaçetin
Ertuğrul
E
Haykir
Rahime
R
D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000473:pathology; D001653:Bile Ducts, Intrahepatic / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D018281:Cholangiocarcinoma / Q000473:pathology; D003287:Contrast Media; D004444:Echinococcosis, Hepatic / Q000473:pathology; D004492:Edetic Acid / Q000031:analogs & derivatives*; D005260:Female; D020518:Focal Nodular Hyperplasia / Q000473:pathology; D006391:Hemangioma / Q000473:pathology*; D006801:Humans; D007089:Image Enhancement; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000473:pathology* / Q000556:secondary; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives*
D003287:Contrast Media; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid